Gut microbiota signatures in cystic fibrosis: Loss of host CFTR function drives the microbiota enterophenotype

Background Cystic fibrosis (CF) is a disorder affecting the respiratory, digestive, reproductive systems and sweat glands. This lethal hereditary disease has known or suspected links to the dysbiosis gut microbiota. High-throughput meta-omics-based approaches may assist in unveiling this complex network of symbiosis modifications. Objectives The aim of this study was to provide a predictive and functional model of the gut microbiota enterophenotype of pediatric patients affected by CF under clinical stability. Methods Thirty-one fecal samples were collected from CF patients and healthy children (HC) (age range, 1–6 years) and analysed using targeted-metagenomics and metabolomics to characterize the ecology and metabolism of CF-linked gut microbiota. The multidimensional data were low fused and processed by chemometric classification analysis. Results The fused metagenomics and metabolomics based gut microbiota profile was characterized by a high abundance of Propionibacterium, Staphylococcus and Clostridiaceae, including Clostridium difficile, and a low abundance of Eggerthella, Eubacterium, Ruminococcus, Dorea, Faecalibacterium prausnitzii, and Lachnospiraceae, associated with overexpression of 4-aminobutyrate (GABA), choline, ethanol, propylbutyrate, and pyridine and low levels of sarcosine, 4-methylphenol, uracil, glucose, acetate, phenol, benzaldehyde, and methylacetate. The CF gut microbiota pattern revealed an enterophenotype intrinsically linked to disease, regardless of age, and with dysbiosis uninduced by reduced pancreatic function and only partially related to oral antibiotic administration or lung colonization/infection. Conclusions All together, the results obtained suggest that the gut microbiota enterophenotypes of CF, together with endogenous and bacterial CF biomarkers, are direct expression of functional alterations at the intestinal level. Hence, it’s possible to infer that CFTR impairment causes the gut ecosystem imbalance.This new understanding of CF host-gut microbiota interactions may be helpful to rationalize novel clinical interventions to improve the affected children’s nutritional status and intestinal function.

[1]  Aliza K Fink,et al.  Data that empower: The success and promise of CF patient registries , 2017, Pediatric pulmonology.

[2]  L. Saiman,et al.  Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[3]  P. Paci,et al.  Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta‐omics‐based approach , 2017, Hepatology.

[4]  S. Lynch,et al.  The Human Intestinal Microbiome in Health and Disease. , 2016, The New England journal of medicine.

[5]  Joseph M. Campos,et al.  Different next generation sequencing platforms produce different microbial profiles and diversity in cystic fibrosis sputum. , 2016, Journal of microbiological methods.

[6]  A. Gasbarrini,et al.  The role of diet on gut microbiota composition. , 2016, European review for medical and pharmacological sciences.

[7]  B. Strandvik,et al.  ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. , 2016, Clinical nutrition.

[8]  T. Thomas,et al.  Disrupted progression of the intestinal microbiota with age in children with cystic fibrosis , 2016, Scientific Reports.

[9]  J. Parkhill,et al.  Respiratory microbiota resistance and resilience to pulmonary exacerbation and subsequent antimicrobial intervention , 2015, The ISME Journal.

[10]  W. Buurman,et al.  Evidence for a Cystic Fibrosis Enteropathy , 2015, PloS one.

[11]  W. D. de Vos,et al.  Phylogenetic and Metabolic Tracking of Gut Microbiota during Perinatal Development , 2015, PloS one.

[12]  M. Zizzo,et al.  GABA and GABA receptors in the gastrointestinal tract: from motility to inflammation. , 2015, Pharmacological research.

[13]  W. Bernhard,et al.  Plasma Phosphatidylcholine Alterations in Cystic Fibrosis Patients: Impaired Metabolism and Correlation with Lung Function and Inflammation , 2015, Cellular Physiology and Biochemistry.

[14]  Garry R. Cutting,et al.  Cystic fibrosis genetics: from molecular understanding to clinical application , 2014, Nature Reviews Genetics.

[15]  Ian M. Balfour-Lynn,et al.  European Cystic Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis Centre , 2014, Journal of Cystic Fibrosis.

[16]  Laura Viviani,et al.  European Cystic Fibrosis Society Standards of Care: Quality Management in cystic fibrosis. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[17]  P. Gilligan Infections in Patients with Cystic Fibrosis , 2014, Clinics in Laboratory Medicine.

[18]  A. Urbani,et al.  Proteomics boosts translational and clinical microbiology. , 2014, Journal of proteomics.

[19]  G. Xie,et al.  Metabolomics approaches for characterizing metabolic interactions between host and its commensal microbes , 2013, Electrophoresis.

[20]  R. D. De Lisle,et al.  The cystic fibrosis intestine. , 2013, Cold Spring Harbor perspectives in medicine.

[21]  F. De Filippis,et al.  Exploring the Sources of Bacterial Spoilers in Beefsteaks by Culture-Independent High-Throughput Sequencing , 2013, PloS one.

[22]  V. Mai,et al.  Intestinal Dysbiosis and Depletion of Butyrogenic Bacteria in Clostridium difficile Infection and Nosocomial Diarrhea , 2013, Journal of Clinical Microbiology.

[23]  D. Gottardi,et al.  Integration of datasets from different analytical techniques to assess the impact of nutrition on human metabolome , 2012, Front. Cell. Inf. Microbio..

[24]  Jingxin Li,et al.  A novel role of intestine epithelial GABAergic signaling in regulating intestinal fluid secretion. , 2012, American journal of physiology. Gastrointestinal and liver physiology.

[25]  Eric P. Nawrocki,et al.  An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea , 2011, The ISME Journal.

[26]  L. Laghi,et al.  Duodenal and faecal microbiota of celiac children: molecular, phenotype and metabolome characterization , 2011, BMC Microbiology.

[27]  Maarten Bekaert,et al.  Cross-Sectional and Longitudinal Comparisons of the Predominant Fecal Microbiota Compositions of a Group of Pediatric Patients with Cystic Fibrosis and Their Healthy Siblings , 2011, Applied and Environmental Microbiology.

[28]  A. Smilde,et al.  Double-check: validation of diagnostic statistics for PLS-DA models in metabolomics studies , 2011, Metabolomics.

[29]  S. Innis,et al.  Plasma choline depletion is associated with decreased peripheral blood leukocyte acetylcholine in children with cystic fibrosis. , 2011, The American journal of clinical nutrition.

[30]  Robert C. Edgar,et al.  Search and clustering orders of magnitude faster than BLAST , 2010, Bioinform..

[31]  R. Knight,et al.  Rapid denoising of pyrosequencing amplicon data: exploiting the rank-abundance distribution , 2010, Nature Methods.

[32]  William A. Walters,et al.  QIIME allows analysis of high-throughput community sequencing data , 2010, Nature Methods.

[33]  Beatrice Vitali,et al.  Impact of a synbiotic food on the gut microbial ecology and metabolic profiles , 2010, BMC Microbiology.

[34]  M. Rosenfeld,et al.  Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. , 2009, The Journal of pediatrics.

[35]  M. Rantalainen,et al.  Top-down systems biology modeling of host metabotype-microbiome associations in obese rodents. , 2009, Journal of proteome research.

[36]  P. Farrell,et al.  The prevalence of cystic fibrosis in the European Union. , 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[37]  S. Allison,et al.  Resistance, resilience, and redundancy in microbial communities , 2008, Proceedings of the National Academy of Sciences.

[38]  E. Vaughan,et al.  1H NMR metabolite profiling of feces as a tool to assess the impact of nutrition on the human microbiome , 2008, NMR in biomedicine.

[39]  M. Kaufmann,et al.  Revised Approach for Identification of Isolates within the Burkholderia cepacia Complex and Description of Clinical Isolates Not Assigned to Any of the Known Genomovars , 2007, Journal of Clinical Microbiology.

[40]  J. Tiedje,et al.  Naïve Bayesian Classifier for Rapid Assignment of rRNA Sequences into the New Bacterial Taxonomy , 2007, Applied and Environmental Microbiology.

[41]  Ben Lacy Costello,et al.  The FASEB Journal • Research Communication Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease , 2022 .

[42]  P. Vandamme,et al.  Transmission of Burkholderia cepacia Complex: Evidence for New Epidemic Clones Infecting Cystic Fibrosis Patients in Italy , 2005, Journal of Clinical Microbiology.

[43]  S. J. James,et al.  Phosphatidylcholine and lysophosphatidylcholine excretion is increased in children with cystic fibrosis and is associated with plasma homocysteine, S-adenosylhomocysteine, and S-adenosylmethionine. , 2005, The American journal of clinical nutrition.

[44]  A. Kaplan,et al.  A Beginner's Guide to Partial Least Squares Analysis , 2004 .

[45]  R. Rowntree,et al.  The Phenotypic Consequences of CFTR Mutations , 2003, Annals of human genetics.

[46]  M. Barker,et al.  Partial least squares for discrimination , 2003 .

[47]  K. Phillips,et al.  Comparison of alcohol shock enrichment and selective enrichment for the isolation of Clostridium difficile , 1987, Epidemiology and Infection.

[48]  R E COOKE,et al.  A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. , 1959, Pediatrics.

[49]  J. Beck,et al.  Microbiome in the pathogenesis of cystic fibrosis and lung transplant‐related disease , 2017, Translational research : the journal of laboratory and clinical medicine.

[50]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .